Vis enkel innførsel

dc.contributor.authorDebik, Julia Barbara
dc.contributor.authorEuceda, Leslie R.
dc.contributor.authorLundgren, Steinar
dc.contributor.authorGythfeldt, Hedda
dc.contributor.authorGarred, Øystein
dc.contributor.authorBorgen, Elin
dc.contributor.authorEngebråten, Olav
dc.contributor.authorBathen, Tone Frost
dc.contributor.authorGiskeødegård, Guro F.
dc.date.accessioned2020-02-07T13:24:05Z
dc.date.available2020-02-07T13:24:05Z
dc.date.created2020-01-11T04:19:18Z
dc.date.issued2019
dc.identifier.citationJournal of Proteome Research. 2019, 18 (10), 3649-3660.nb_NO
dc.identifier.issn1535-3893
dc.identifier.urihttp://hdl.handle.net/11250/2640460
dc.description.abstractPatients with locally advanced breast cancer have a worse prognosis compared to patients with localized tumors and require neoadjuvant treatment before surgery. The aim of this study was to characterize the systemic metabolic effect of neoadjuvant chemotherapy in patients with large primary breast cancers and to relate these changes to treatment response and long-term survival. This study included 132 patients with large primary breast tumors randomized to receive neoadjuvant chemotherapy with or without the addition of the antiangiogenic drug Bevacizumab. Tumor biopsies and serum were collected before and during treatment and, serum additionally 6 weeks after surgery. Samples were analyzed by nuclear magnetic resonance spectroscopy (NMR). Correlation analysis showed low correlations between metabolites measured in cancer tissue and serum. Multilevel partial least squares discriminant analysis (PLS-DA) showed clear changes in serum metabolite levels during treatment (p-values ≤ 0.001), including unfavorable changes in lipid levels. PLS-DA revealed metabolic differences between tissue samples from survivors and nonsurvivors collected 12 weeks into treatment with an accuracy of 72% (p-value = 0.005); however, this was not evident in serum samples. Our results demonstrate a potential clinical application for serum-metabolomics for patient monitoring during and after treatment, and indicate potential for tissue NMR spectroscopy for predicting patient survival.nb_NO
dc.language.isoengnb_NO
dc.publisherAmerican Chemical Societynb_NO
dc.titleAssessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patientsnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber3649-3660nb_NO
dc.source.volume18nb_NO
dc.source.journalJournal of Proteome Researchnb_NO
dc.source.issue10nb_NO
dc.identifier.doi10.1021/acs.jproteome.9b00316
dc.identifier.cristin1770622
dc.description.localcodeLocked until 4.9.2020 due to copyright restrictions. This document is the Accepted Manuscript version of a Published Work that appeared in final form in [Journal of Proteome Research], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.jproteome.9b00316nb_NO
cristin.unitcode194,65,25,0
cristin.unitcode1920,12,0,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameKreftklinikken
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel